Biogen Idec has initiated a randomized, controlled, registration trial of an investigational anti-CD23 monoclonal antibody, lumiliximab, for patients with chronic lymphocytic leukemia (CLL). The trial will compare treatment with lumiliximab in combination with fludaribine, cyclophosphamide and rituximab (FCR), to FCR alone in patients with CLL that has relapsed or failed to respond to initial therapy. Lumiliximab was recently granted Fast Track and Orphan Drug designations by the FDA for this in...